The fund aims to provide capital growth by investing in a diversified global portfolio of predominantly equities. The fund is actively managed, and is not constrained by any requirement to track indices or conform to investment fashion.
Name | % Net Assets |
---|---|
Science Group | 3.7% |
Runge | 2.6% |
Novartis | 2.2% |
Groupe Bruxelles Lambert | 2.2% |
Leucadia National | 1.6% |
Continental Building Products | 1.6% |
Castings | 1.6% |
ExxonMobil | 1.6% |
Microgen | 1.6% |
Balfour Beatty | 1.6% |
Key | % Net Assets |
---|---|
Science Group | 3.7% |
Runge | 2.6% |
Novartis | 2.2% |
Groupe Bruxelles Lambert | 2.2% |
Other | 89.3% |
Date | 16-Nov-2022 |
---|---|
NAV | 545.98p |
Currency | GBP |
Change | 545.98p |
% | n/a |
YTD change | 545.98p |
YTD % | n/a |
Fund Inception | 01/12/1999 |
---|---|
Fund Manager | Alex Grispos |
TER | 1.56 (15-Mar-2013) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £100 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.18 |
You are here: research